Screener
Xeris Biopharma Holdings, Inc. XERS Net Change in Cash
Net Change in Cash at other companies
Other financials
Where this comes from
Reported directly by Xeris Biopharma Holdings, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect.
The source filing: Xeris Biopharma Holdings, Inc.’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:07 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001867096-26-000065
| Line item | Six Months Ended June 30, 2026 | 2025 |
|---|---|---|
| Proceeds from issuance of common shares in settlement of warrants | 7,933 | — |
| Repurchase of common stock withheld for taxes | (17,208) | (8,858) |
| Net cash used in financing activities | (6,894) | (2,195) |
| Net increase (decrease) in cash, cash equivalents, and restricted cash | 10,705 | (12,336) |
| Cash, cash equivalents and restricted cash, beginning of year | 115,063 | 75,744 |
| Cash, cash equivalents and restricted cash, end of quarter | $125,768 | $63,408 |
| 2026 | 2025 | |
| Supplemental schedule of cash flow information(1): |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Xeris Biopharma Holdings, Inc.'s net change in cash?
- Xeris Biopharma Holdings, Inc. (XERS) reported net change in cash of $10M in Q2 2026.
- How has Xeris Biopharma Holdings, Inc.'s net change in cash changed year-over-year?
- Xeris Biopharma Holdings, Inc.'s net change in cash increased by 1083.1% year-over-year, from $845K to $10M.
- What does net change in cash mean?
- Total increase or decrease in cash during the period — the sum of operating, investing, financing cash flows plus FX effects.
Ask your AI about Xeris Biopharma Holdings, Inc.'s net change in cash.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude